Transgene signs pre-clinical AIDS vaccine manufacturing agreement
Transgene releaseTransgene (Nasdaq: TRGNY) announced today that it has entered into an agreement with the French AIDS Research Agency (Agence Nationale de Recherches sur le SIDA /ANRS) and the French Institut for Health and Medical Research (Institut National de la Santé et de la Recherche Médicale / INSERM) to construct and manufacture pre-clinical lots of a novel AIDS vaccine. Transgene will make the constructs consisting of Modified Vaccinia Ankara (MVA) vectors carrying AIDS virus epitopes from Gag, Nef and Pol genes and will manufacture the pre- clinical lots. INSERM, which owns the intellectual property of the Nef protein fragments, will conduct the immunological pre-clinical testing of the vaccine constructs together with ANRS. Under the terms of this short-term service agreement, Transgene will receive payment from ANRS.
—Posted: November 3, 2003
More news headlines: This week | Last week | Search archive